RONALD DOUGLAS ELLIS
Medical Practice in Philadelphia, PA
License number
Pennsylvania LL000034P
Category
Medicine
Type
Limited License-Professor
Address
Address
Philadelphia, PA 19144
Personal information
See more information about RONALD DOUGLAS ELLIS at radaris.comName
Address
Phone
5131 Sheldon St, Philadelphia, PA 19144
527 E Vine St, Pottstown, PA 19464
5311 Castor Ave, Philadelphia, PA 19124
3620 7Th Ave, Beaver Falls, PA 15010
Professional information
Ronald Ellis - Philadelphia, PA
Work:
Resources for Human Development - Philadelphia, PA
Residential Aide Recall - Media, PA
Machine Operator LA Services of Virginia - Hampton, VA
Relocator
Residential Aide Recall - Media, PA
Machine Operator LA Services of Virginia - Hampton, VA
Relocator
Education:
Grove City High School - Grove City, PA
Diploma
Diploma
Vaccine Against Varicella-Zoster Virus
US Patent:
4769239, Sep 6, 1988
Filed:
Aug 21, 1984
Appl. No.:
6/642983
Inventors:
Ronald W. Ellis - Overbrook Hills PA
Paul M. Keller - Lansdale PA
Paul M. Keller - Lansdale PA
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
A61K 3912, A61K 3925, C12P 2100, C12N 1500
US Classification:
424 89
Abstract:
A gene of varicella-zoster virus (VZV) which encodes immunogenic outer surface viral proteins has been identified through DNA sequence analysis. Fragments of the DNA have been cloned into a vector which, when placed into a host organism, expresses proteins which react with human convalescent zoster sera and with monoclonal antibodies which neutralize viral infectivity. These proteins are useful for preparation of a vaccine for VZV.
Method For Producing Hepatitis B Virus Proteins In Yeast
US Patent:
4816564, Mar 28, 1989
Filed:
Jan 31, 1986
Appl. No.:
6/824405
Inventors:
Ronald W. Ellis - Overbrook Hills PA
Arpi Hagopian - Lansdale PA
Peter J. Kniskern - Lansdale PA
Arpi Hagopian - Lansdale PA
Peter J. Kniskern - Lansdale PA
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
C07K 710, C07K 1300
US Classification:
530350
Abstract:
The entire hepatitis B Virus pre-S antigen gene linked in one contiguous reading frame to the hepatitis B virus surface antigen gene has been expressed in Saccharomyces cerevisiae. The expressed protein aggregates into a particulate form which displays the major antigenic sites encoded by both domains, thereby highlighting the utility of yeast as a host for the expression of pre-S domains. This protein is useful in in vitro diagnostic systems and as a vaccine for the treatment and prevention of hepatitis B virus-induced diseases and/or infections.
Vaccine Against Varicella-Zoster Virus
US Patent:
4812559, Mar 14, 1989
Filed:
Mar 23, 1987
Appl. No.:
7/028826
Inventors:
Ronald W. Ellis - Overbrook Hills PA
Paul M. Keller - Lansdale PA
Robert S. Lowe - Harleysville PA
Andrew J. Davison - Glasgow, GB6
Paul M. Keller - Lansdale PA
Robert S. Lowe - Harleysville PA
Andrew J. Davison - Glasgow, GB6
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
C07H 1512, C12P 2102, C12N 1500, C12N 100
US Classification:
536 27
Abstract:
A gene of varicella-zoster virus (VZV) which encodes immunogenic outer surface viral proteins has been identified by DNA sequence analysis. This gene can hybrid select messenger RNA which encodes and expresses a protein which reacts with human convalescent zoster sera and with polyclonal monospecific antisera which neutralize viral infectivity. These proteins are useful for the preparation of a vaccine for VZV.
Dna Encoding Immunogenic Gpiii Glycoprotein Of Varicella-Zoster Virus
US Patent:
5306635, Apr 26, 1994
Filed:
Jun 9, 1992
Appl. No.:
7/896038
Inventors:
Paul M. Keller - Lansdale PA
Mark W. Riemen - Doylestown PA
Ronald W. Ellis - Overbrook Hills PA
Andrew J. Davison - Glasgow, GB6
Robert S. Lowe - Harleysville PA
Mark W. Riemen - Doylestown PA
Ronald W. Ellis - Overbrook Hills PA
Andrew J. Davison - Glasgow, GB6
Robert S. Lowe - Harleysville PA
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
C12N 1538, C12N 510, C12N 119, C12N 121
US Classification:
4352402
Abstract:
A gene of varicella-zoster virus (VZV) which encodes immunogenic outer surface viral proteins has been identified by DNA sequence analysis. Antibodies directed against peptides imputed from the DNA sequence can react with the glycoprotein, which itself is reactive with neutralizing antibodies. The amino-terminal sequence of the purified glycoprotein is identical to a portion of the amino acid sequence imputed from the DNA sequence. This glycoprotein is useful for the preparation of a vaccine against VZV.
Vaccines Comprising Yeast-Derived Hepatits B Virus Polypeptides
US Patent:
5133961, Jul 28, 1992
Filed:
Jun 29, 1987
Appl. No.:
7/004728
Inventors:
Ronald W. Ellis - Overbrook Hills PA
Peter J. Kniskern - Lansdale PA
Hagopian Arpi - Lansdale PA
Peter J. Kniskern - Lansdale PA
Hagopian Arpi - Lansdale PA
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
A61K 3929
US Classification:
424 89
Abstract:
The entire hepatitis B virus pre-S antigen gene linked in one contiguous reading frame to the hepatitus B virus surface antigen gene has been expressed in Saccharomyces cerevisiae. The expressed protein aggregates into a particulate form which displays the major antigenic sites encoded by both domains, thereby highlighting the utility of yeast as a host for the expression of pre-S domains. This protein is useful in in vitro diagnostic systems and as a vaccine for the treatment and prevention of hepatitis B virus-induced diseases and/or infections.
Trains Of Yeast For The Expression Of Heterologous Genes
US Patent:
5068185, Nov 26, 1991
Filed:
Jul 10, 1986
Appl. No.:
6/884114
Inventors:
James E. Hopper - Lebanon PA
Loren D. Schultz - Harleysville PA
Kathryn J. Hofmann - King of Prussia PA
Ronald W. Ellis - Overbrook Hills PA
Loren D. Schultz - Harleysville PA
Kathryn J. Hofmann - King of Prussia PA
Ronald W. Ellis - Overbrook Hills PA
Assignee:
Merck & Co., Inc. - NJ
International Classification:
C12P 2102, C12N 1500, C12N 114, C12N 116, C12N 118, C12N 1581, C12N 119
US Classification:
435 691
Abstract:
The GAL4 protein is rate-limiting in quantity as a positive regulator for galactose-inducible promoters in strains of yeast. Novel strains are described in which the GAL4 protein can be overproduced in a regulatable fashion. These strains are useful for the regulatable expression in yeast of heterologous genes whose expression is driven by a galactose-inducible promoter.
Vaccine Against Varicella-Zoster Virus
US Patent:
4686101, Aug 11, 1987
Filed:
Aug 2, 1985
Appl. No.:
6/762001
Inventors:
Ronald W. Ellis - Overbrook Hills PA
Robert S. Lowe - Harleysville PA
Paul M. Keller - Lansdale PA
Andrew J. Davison - Glasgow, GB6
Robert S. Lowe - Harleysville PA
Paul M. Keller - Lansdale PA
Andrew J. Davison - Glasgow, GB6
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
A61K 3900, C07K 1300
US Classification:
424 88
Abstract:
A gene of varicella-zoster virus (VZV) which encodes immunogenic outer surface viral proteins has been identified by DNA sequence analysis. This gene can hybrid select messenger RNA which encodes and expresses a protein which reacts with human canvalescent zoster sera and with polyclonal monospecific antisera which neutralize viral infectivity. These proteins are useful for the preparation of a vaccine for VZV.
Varicella-Zoster Virus As A Live Recombinant Vaccine
US Patent:
5310668, May 10, 1994
Filed:
Feb 27, 1992
Appl. No.:
2/846751
Inventors:
Ronald W. Ellis - Overbrook Hills PA
Elliott Kieff - Brookline MA
Edward M. Scolnick - Wynnewood PA
Robert S. Lowe - Harleysville PA
Elliott Kieff - Brookline MA
Edward M. Scolnick - Wynnewood PA
Robert S. Lowe - Harleysville PA
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
C12N 1586, C12N 701, A61K 39295, A61K 3925
US Classification:
4351723
Abstract:
A vaccine strain of varicella-zoster virus (VZV), tested in clinical trials, is capable of preventing chickenpox in children. This virus has been modified by the introduction into its genome of heterologous DNA which encodes an immunogenic polypeptide of another human pathogen. This heterologous polypeptide is expressed in cells infected by the recombinant virus. Such recombinant VZV is useful as a vaccine for chickenpox as well as for heterologous pathogens.
Method For Producing Hepatitis B Virus Proteins In Yeast
US Patent:
4963483, Oct 16, 1990
Filed:
Oct 13, 1987
Appl. No.:
7/107812
Inventors:
Ronald W. Ellis - Overbrook Hills PA
Arpi Hagopian - Lansdale PA
Peter J. Kniskern - Lansdale PA
Donna L. Montgomery - Chalfont PA
Arpi Hagopian - Lansdale PA
Peter J. Kniskern - Lansdale PA
Donna L. Montgomery - Chalfont PA
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
C12N 1500, C12N 500, C12P 2100, A61K 3900
US Classification:
435 693
Abstract:
The hepatitis B virus preS2 antigen gene linked in one contiguous reading frame to the hepatitis B virus surface antigen gene has been expressed in Saccharomyces cerevisiae utilizing an optimized plasmid construction. The expressed protein aggregates into a particulate form which displays the major antigenic sites encoded by both domains, thereby highlighting the utility of yeast as a host for the high level expression of the preS2 as well as the S domain. This protein is useful in in vitro diagnostic systems and as a vaccine for the treatment and prevention of hepatitis B virus-induced diseases and/or infections.